Last reviewed · How we verify
NCT04504578: CACXL
Efficacy and Safety ofCACXL in the Treatment of Keratoconus With Thin Corneas
NA trial testing contact lens assisted corneal cross linking in Progressive Keratoconus in 30 participants. Completed in 1 February 2019.
1 January 2019
Quick facts
| Lead sponsor | Kasr El Aini Hospital |
|---|---|
| Phase | NA |
| Status | Completed |
| Study type | INTERVENTIONAL |
| Allocation | na |
| Design | single group |
| Masking | none |
| Primary purpose | treatment |
| Enrollment | 30 |
| Start date | 1 January 2018 |
| Primary completion | 1 January 2019 |
| Estimated completion | 1 February 2019 |
| Sites | 1 location across Egypt |
Drugs / interventions tested
- contact lens assisted corneal cross linking
Conditions studied
- Progressive Keratoconus — all drugs for Progressive Keratoconus →
Sponsor
Kasr El Aini Hospital
Who can join
Adults 18 to 40, any sex, with Progressive Keratoconus. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
The aim of this study is to detect the safety and effectiveness of contact lens assisted corneal cross linking in managing progressive keratoconus with thin corneas CACXL was done for 40 eyes of 30 of keratoconic patients presented to cornea outpatient clinic in Kasr Alainy teaching hospital The UDVA ,BDVA KMAX, thinnest corneal thickness pre-operative and 9 months postoperatively and the endothelial cell count was measured preoperative and 3 months postoperative Demarcation line was measured after 1 month by using ASOCT There was statistical significant difference in UDVA and BDVA, there was stabilization of Kmax there was decrease in endothelial cell count but not statistically significant According to results the procedure seems to be effective and safe un managing progressive keratoconus.
Publications & conference data
1 peer-reviewed publication reference this trial (live from Europe PMC):
-
Efficacy and Safety of Contact Lens-Assisted Corneal Crosslinking in the Treatment of Keratoconus With Thin Corneas.
Nour MM, El-Agha MH, Sherif AM, Shousha SM. · · 2021 · cited 9× · PMID 34001713 · DOI 10.1097/icl.0000000000000799
Verify or expand the search:
- PubMed search for NCT04504578
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other Kasr El Aini Hospital trials
Trials by the same sponsor.
- NCT07438652 — Effect of Mediterranean vs Paleolithic Diet on RA Activity, Sarcopenia and QOL: 12-Week RCT · NA · recruiting
- NCT07488039 — Labroplasty in Cases of Anterior Shoulder Instability With Subcritical Glenoid Bone Loss · NA · recruiting
- NCT07274280 — Comparative Evaluation of Ambu AuraGain, LarySeal Pro and I-gel in Pediatric Airway Management for Day-Case Surgery Unde · NA · not yet recruiting
- NCT07348146 — Hand-Sewn vs. Stapled Anastomosis in SADI-S: Early Postoperative Complications. · NA · enrolling by invitation
- NCT07077265 — Comparing Two Different Norepinephrine Infusion Rates for Prophylaxis Against Spinal-induced Hypotension in Elderly · NA · completed
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT04504578 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Kasr El Aini Hospital
- Last refreshed: 7 August 2020
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04504578.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing